BRMS1 suppresses the PI3K/AKT/mTOR pathway to regulate autophagy in multiple myeloma

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Multiple myeloma (MM) is a hematologic malignancy characterized by uncontrolled plasma cell proliferation.
• The role of metastasis suppressors, such as breast cancer metastasis suppressor 1 (BRMS1), in MM pathogenesis is not well understood.
• Identifying novel tumor suppressors is crucial for developing effective MM therapies.

Purpose of the Study:

• To investigate the role of BRMS1 in the progression of multiple myeloma.
• To elucidate the molecular mechanisms underlying BRMS1's function in MM cells.
• To explore BRMS1 as a potential therapeutic target for MM.

Main Methods:

• Quantitative real-time PCR and Western blotting to assess BRMS1 expression in MM samples and cell lines.
• In vitro functional assays including cell proliferation, migration, invasion, apoptosis, and autophagy flux assays.
• Pharmacological manipulation of autophagy and investigation of the PI3K/AKT/mTOR signaling pathway.

Main Results:

• BRMS1 expression is significantly downregulated in MM patient samples and cell lines.
• Overexpression of BRMS1 suppresses MM cell proliferation, migration, and invasion, while enhancing apoptosis and autophagic flux.
• Knockdown of BRMS1 promotes MM cell tumorigenic behaviors, and its tumor-suppressive effects are dependent on autophagy regulation via the PI3K/AKT/mTOR pathway.

Conclusions:

• BRMS1 functions as a tumor suppressor in multiple myeloma.
• BRMS1 regulates MM progression through modulation of autophagy and apoptosis.
• Targeting BRMS1-mediated autophagy presents a potential novel therapeutic strategy for MM treatment.